DUBLIN--(BUSINESS WIRE)--The "IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering Technology, Application - Global Forecast to 2031" report has been added to ...

GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic ...

Register for our upcoming webinar “Accelerate your IVD assay development with the unique support of the Dynabeads team” and learn how Dynabeads technology and commercial partnership can help ...

REDDING, Calif., Oct. 24, 2024 /PRNewswire/ -- According to a new market research report, 'IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering (Assay Development, ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ ...

Advanced technologies are taking in vitro diagnostics (IVD) far beyond lateral flow tests or immunoassays. Molecular technologies like PCR and NGS are rapidly expanding in the diagnostic assay ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...

Firm will seek approval of a range of diagnostic assays for the platform. Qiagen confirmed the receipt or FDA 510(k) clearance for both its Rotor-Gene Q MDx real-time PCR platform, and also the artus ...

QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics ...